tldrdailynews.com logo

Rasonque Debuts in Pancreatic Cancer as Investors Eye a Historic Launch

1 min read
Source: Fierce Pharma
Rasonque Debuts in Pancreatic Cancer as Investors Eye a Historic Launch
Photo: Fierce Pharma
TL;DR

Revolution Medicines wins FDA approval for Rasonque (daraxonrasib) in metastatic pancreatic cancer, triggering optimism of a historic oncology launch and potential multi‑billion sales, but raising questions about first‑line use, payer coverage, and how quickly patients move from expanded‑access to commercial treatment amid a $39,800 monthly price and a broad label whose criteria for multiagent therapy remain unclear.

Topics:businesshealthcare#drug-pricing#expanded-access-program#healthcare#pancreatic-cancer#rasonque#revolution-medicines
Share this article
  1. As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground  Fierce Pharma
  2. FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease  WSJ
  3. FDA Approves RASONQUE™ (daraxonrasib)  Pancreatic Cancer Action Network
  4. New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many  The New York Times
  5. FDA Approves RevMed’s Breakthrough Pill for Pancreatic Cancer  Bloomberg

Want the full story? Read the original reporting

Read on Fierce Pharma